Hikma Eyes Return To Growth After Further Cutting Generics Forecasts

Injectables And Branded Increases Offset 18% Sales Slide For Generics Unit In First Half

Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.

Light at the end of the tunnel, red
Hikma sees light at the end of the tunnel for its generics business • Source: Shutterstock

Competitive pressures in the US have led Hikma to once again slash its Generics guidance for 2022, cutting its full-year sales expectations for the unit to $650m-$675m, with a core operating margin expected to come in at 15%-16%, in the face of “persistent challenges” in the US generics market.

Challenges highlighted by Brian Hoffman, president of the Generics division, included defending some of the firm’s top products in the face of increased competition – after fresh rivals to Advair Diskus (fluticasone/salmeterol) and Vascepa (icosapent ethyl) recently entered the market (Also see "Hikma Still Sees Value In Generic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By 

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By 

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By 

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By 

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.